Medicare Advantage Denial Forces 70-Year-Old Into ER Over $8K Monthly Drug

Margaret Hvatum, a 70-year-old Missouri resident, was denied prior authorization for the life-saving drug Hizentra by Humana under her Medicare Advantage plan, leaving her unable to afford the $8,141.94 monthly cost. Missing doses led to severe infections requiring emergency care, with Humana initially rejecting hospital coverage before reversing both decisions post-appeal. Her case highlights rising concerns over Medicare Advantage's prior authorization hurdles and insurers' cost-cutting measures, as millions face plan changes amid carrier exits.

Escalating Prior Authorization Denial Trends in Medicare Advantage

■Humana and other insurers report increased prior authorization rejections under Medicare Advantage plans.

■High-cost medications like Hizentra expose gaps in coverage, pushing beneficiaries into financial and medical crises.

■Carrie Graham of Georgetown University notes that private insurers' denial freedom creates systemic vulnerabilities in care access.

■Plan switching due to insurer exits has left millions navigating inconsistent coverage rules, amplifying healthcare risks for seniors.

Ege Kaan Analysis: Medicare Advantage's cost-saving appeal masks underlying risks in prior authorization protocols, creating volatility in healthcare spending. Insurers like Humana and UnitedHealth face scrutiny as they tighten coverage criteria to manage expenses. This trend could influence investor sentiment toward healthcare stocks and reshape risk-adjustment strategies in the sector.